Researchers have engineered a tobacco plant to produce five psychedelic compounds at the same time, including psilocybin, DMT, psilocin, bufotenin, and 5-MeO-DMT. The work, published in Science Advances, reconstructed full biosynthetic pathways from fungi, plants, and animals inside a single plant host, Nicotiana benthamiana. The result is a living factory that assembles all five tryptamine-based psychedelics through transient gene expression, a technique that could reshape how scientists study and eventually manufacture these molecules for therapeutic research.
What is verified so far
The core claim rests on a peer-reviewed paper indexed on PubMed under PMID 41921002. That study confirms that researchers reconstructed full biosynthetic pathways in a plant host, yielding five distinct psychedelic tryptamines: DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT. The phrase “three kingdoms” refers to the sourcing of enzymes from fungi, plants, and animals, a design choice that distinguishes this platform from earlier single-kingdom approaches and demonstrates that enzymes from very different organisms can operate together inside one plant cell.
The team used Nicotiana benthamiana, a species of tobacco widely favored in synthetic biology because it grows quickly, tolerates foreign gene expression well, and produces large leaves suitable for infiltration-based experiments. According to a summary on Phys.org, the researchers mapped the DMT pathway and achieved simultaneous production of all five compounds through transient expression and infiltration, a method in which bacteria carrying the desired genes are injected into leaf tissue. Within days, the plant’s own cellular machinery reads those genes and assembles the corresponding enzymes, which then convert simple precursors into the desired psychedelic products.
Supporting genomic data is publicly available through the associated BioProject record, which links to sequence resources including SRA experiments and related nucleotide and TSA entries. This dataset provides a transparent view of the constructs and expression profiles used in the work, allowing other laboratories to check the sequences, replicate the assembly, and test alternative pathway designs. Open access to these resources is increasingly seen as essential for reproducibility in synthetic biology, especially when complex multi-enzyme pathways are involved.
The cross-kingdom enzyme strategy draws directly on earlier discoveries. A 2023 study of cane toad biochemistry identified an N-methyltransferase that converts primary indolethylamines into tertiary psychedelic amines, the chemical class that includes bufotenin and 5-MeO-DMT. That animal-derived enzyme is now repurposed inside the tobacco chassis to extend the plant’s native tryptamine metabolism into new territory. On the fungal side, the enzymatic route for psilocybin biosynthesis using the enzymes PsiD, PsiK, and PsiM was established in a foundational 2017 investigation, and those same pathway components appear to have been assembled for in-plant production of psilocin and psilocybin in the new work. By combining these fungal and animal enzymes with plant-derived steps, the researchers effectively stitched together a modular toolkit for psychedelic synthesis.
In practical terms, the demonstration shows that a single plant leaf can host multiple, partially overlapping pathways that branch from a common tryptamine backbone. DMT, psilocin, and psilocybin share early steps, while bufotenin and 5-MeO-DMT diverge at later methylation reactions. Managing this branching architecture without overwhelming the host requires careful tuning of expression levels and subcellular localization, aspects that the Science Advances team appears to have addressed through construct design and promoter choice, even if the popular summaries do not delve into those technical details.
What remains uncertain
The most significant gap in publicly available reporting is the absence of detailed yield data. While the Science Advances paper confirms detection of all five compounds, no specific titers, concentrations per gram of leaf tissue, or stability measurements have surfaced in the accessible summaries. Without those numbers, it is difficult to judge whether this platform could eventually compete with microbial fermentation or chemical synthesis for practical production. For now, readers should treat the achievement as a proof of concept: it shows that plants can be programmed to assemble complex psychedelic mixtures, but it does not yet demonstrate economically meaningful output.
A second open question is whether the transient expression system used here can translate into stable, heritable plant lines. Transient infiltration is a standard laboratory technique, but it does not produce plants that pass the engineered traits to their offspring. The primary sources and the supporting citation-trail literature do not address long-term genetic stability, agronomic performance, or field-trial feasibility. Creating a stable transgenic tobacco line that reliably produces all five compounds across generations would be a separate and substantial engineering challenge, likely requiring integration of large DNA cassettes, control of insertion sites, and strategies to avoid gene silencing.
Regulatory implications also remain unaddressed by the research team, at least in publicly available statements. All five compounds are classified as Schedule I substances in the United States and are similarly controlled in many other jurisdictions. Producing them in greenhouse-grown plants raises questions about containment, tracking, and legal authorization that differ from those posed by laboratory synthesis or microbial fermentation in closed bioreactors. Institutions would need to demonstrate that engineered plants cannot escape, cross-pollinate with related species, or be diverted for unauthorized use. No official records or institutional statements from the researchers’ home institution, the Weizmann Institute of Science, have yet outlined plans for navigating these constraints.
Another uncertainty is how the plant platform compares directly with microbial systems. A recent review of pathway engineering for psychedelic biosynthesis situates the tobacco work within broader efforts to produce DMT, 5-MeO-DMT, bufotenin, and psilocybin in bacteria and yeast, summarizing common strategies such as codon optimization, cofactor balancing, and transporter engineering. However, the review does not provide head-to-head yield comparisons between plant and microbial hosts. One hypothesis is that plants could outperform microbes by offering natural vacuoles and other organelles that sequester toxic intermediates or end products, thereby reducing stress on the host. This idea is conceptually attractive but, in the context of psychedelic tryptamines, remains speculative without direct experimental benchmarks.
There are also unresolved questions about metabolic burden and plant health. Packing multiple heterologous pathways into a single leaf can divert significant cellular resources toward non-native chemistry. Over time, that diversion might impair growth, photosynthesis, or defense responses, especially if the products or intermediates are bioactive toward the plant itself. The current reporting confirms that the engineered leaves produce detectable psychedelics, but does not yet describe longer-term physiological impacts, potential trade-offs with biomass accumulation, or strategies to confine production to specific tissues.
How to read the evidence
The strongest evidence in this case is the Science Advances article itself, which has passed peer review and is indexed in major databases. Its associated BioProject data, plasmid maps, and expression analyses provide a verifiable trail of constructs and experimental conditions. Together, these primary sources confirm the central technical claim: five psychedelic tryptamines were produced in a single plant host using enzymes drawn from three biological kingdoms, implemented via transient expression in Nicotiana benthamiana.
The supporting enzyme studies, including the cane toad N-methyltransferase characterization and the earlier psilocybin pathway elucidation, supply mechanistic credibility: each enzymatic step in the assembled pathways has been independently validated in other contexts. The newer review on psychedelic pathway engineering shows that the tobacco system is part of a broader trend toward biological production of these compounds, rather than an isolated curiosity. At the same time, the lack of publicly discussed yield metrics, stability data, and regulatory frameworks means that some of the more ambitious interpretations (such as near-term agricultural production of psychedelics) go beyond what the evidence currently supports.
For readers, a balanced interpretation is to see this work as a vivid demonstration of what modern synthetic biology can do: transplant multi-step metabolic pathways across kingdoms, combine them in a single host, and generate complex natural products that once required specialized fungi, animals, or chemical synthesis. It does not yet resolve whether plants will become the dominant platform for psychedelic manufacturing, nor does it answer how societies will regulate crops that blur the line between agriculture and controlled-substance production. Those questions will require further experiments, comparative studies, and policy debates. For now, the engineered tobacco plant stands as a powerful proof of concept that biology itself can be rewired to explore, and perhaps eventually supply, the expanding frontier of psychedelic science.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
